-
31.发明申请MICROPARTICULATED VACCINES FOR THE ORAL OR NASAL VACCINATION AND BOOSTERING OF ANIMALS INCLUDING FISH 有权用于口服或鼻内接种疫苗的微生物疫苗和包括鱼类在内的动物饲养公开(公告)号：US20120040010A1
公开(公告)日：2012-02-16
申请号：US13260661
申请日：2010-03-26
Applicant: Moti Harel , Brian Carpenter
Inventor： Moti Harel , Brian Carpenter
CPC classification number: A61K39/39 , A61K9/0043 , A61K9/006 , A61K9/5015 , A61K39/00 , A61K39/0208 , A61K39/0233 , A61K39/0241 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/522 , A61K2039/5254 , A61K2039/5258 , A61K2039/541 , A61K2039/542 , A61K2039/543 , A61K2039/552 , A61K2039/55555 , A61K2039/55583 , C12N7/00 , C12N2720/10011 , C12N2720/10023 , C12N2720/10034 , C12N2740/10011 , C12N2740/10034 , C12N2760/10034 , C12N2760/16011 , C12N2760/16022 , C12N2760/16034
Abstract: The invention relates to a composition and a method for manufacturing semi-dry or dry particles containing a mucoadhesive polymer and a bioactive agent such as, but not limited to, an Immunogenic Substance (e.g., a vaccine), that allows the oral or nasal administration and delivery of the bioactive agent essentially unaltered to mucosal surfaces in the animal, including an aquatic animal.
Abstract translation: 本发明涉及一种用于制造半干或干燥颗粒的组合物和方法，其包含粘膜粘附聚合物和生物活性剂，例如但不限于免疫原性物质（例如疫苗），其允许口服或鼻内施用 并且生物活性剂的输送基本上不变化到动物的粘膜表面，包括水生动物。
-
公开(公告)号：US07959927B2
公开(公告)日：2011-06-14
申请号：US12618842
申请日：2009-11-16
Applicant: Hsien-Jue Chu , Wumin Li , Zhichang Xu
Inventor： Hsien-Jue Chu , Wumin Li , Zhichang Xu
IPC: A61K39/295
CPC classification number: A61K9/0024 , A61K39/0241 , A61K39/12 , A61K39/145 , A61K39/39 , A61K47/06 , A61K47/10 , A61K47/32 , A61K2039/521 , A61K2039/525 , A61K2039/552 , A61K2039/55555 , A61K2039/55566 , A61K2039/70 , C12N7/00 , C12N2760/16134 , Y02A50/48
Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA. In another embodiment, the invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
Abstract translation: 本发明提供了一种改良的猪肺炎支原体疫苗组合物，其在单次给药后有利地提供免疫感染。 组合物包含灭活的猪肺炎支原体疫苗和佐剂混合物，其组合在单次施用后提供对猪肺炎支原体感染的免疫，并引起对猪肺炎支原体菌苗特异性的免疫应答，并且包括细胞介导的免疫和局部（分泌型IgA ）免疫力。 在优选的实施方案中，佐剂混合物包含丙烯酸聚合物，最优选CARBOPOL，以及可代谢的油，例如一种或多种不饱和萜烯烃，优选角鲨烯或角鲨烷和聚氧乙烯 - 聚丙烯嵌段共聚物如PLURONIC ®。 疫苗组合物可以任选地包括防腐剂，优选硫柳汞和/或EDTA。 在另一个实施方案中，本发明提供了改进的猪肺炎支原体疫苗组合物，其有利地在单次施用后提供免疫感染，并且包含灭活的猪肺炎支原体菌苗和佐剂或佐剂混合物，其组合提供猪肺炎支原体 单次给药后感染，并引起特异于猪肺炎支原体菌的免疫应答，并与其他疫苗组分结合使用，包括细胞介导的免疫和局部（分泌型IgA）免疫。
-
33.发明申请VACCINE COMPOSITION FOR VACCINATING DOGS AGAINST CANINE INFECTIOUS RESPIRATORY DISEASE (CIRD) 审中-公开用于感染犬感染性呼吸道疾病（CIRD）的疫苗组合物
公开(公告)号：US20110059128A1
公开(公告)日：2011-03-10
申请号：US12816214
申请日：2010-06-15
Applicant: JOHN BROWNLIE , VICTORIA JANE CHALKER , KERSTIN ERLES
Inventor： JOHN BROWNLIE , VICTORIA JANE CHALKER , KERSTIN ERLES
IPC: A61K39/116 , A61K39/02 , A61P31/04 , A61P37/04
CPC classification number: G01N33/6854 , A61K39/0241 , A61K39/092 , A61K39/118 , A61K2039/505 , A61K2039/552 , G01N2333/295 , G01N2333/30 , G01N2333/315 , G01N2800/12
Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.
Abstract translation: 一种用于疫苗接种疫苗的疫苗组合物，其包含以下一种或多种：（a）能够对狗中的链球菌属动物疫苗提供免疫应答的试剂，（b）能够增加狗中支原体的免疫应答的试剂 ，和（c）能够在狗中提高针对衣原体的免疫应答的药剂。
-
34.发明申请PCV2 MYCOPLASMA HYOPNEUMONIAE IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCING SUCH COMPOSITIONS 审中-公开PCV2 MYCOPLASMA HYOPNEUMONIAE IMMUNOGENIC COMPOSITIONS AND METHODS OF PRODUCTING OF THAT COMPOSITIONS
公开(公告)号：US20090317423A1
公开(公告)日：2009-12-24
申请号：US12359023
申请日：2009-01-23
Applicant: Michael Roof , Marc Eichmeyer
Inventor： Michael Roof , Marc Eichmeyer
IPC: A61K39/295
CPC classification number: A61K39/12 , A61K39/0208 , A61K39/0241 , A61K39/39 , A61K2039/525 , A61K2039/545 , A61K2039/552 , A61K2039/55555 , A61K2039/70 , C12N7/00 , C12N2750/10034 , C12N2750/10071
Abstract: Multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of M. hyo infection, preferably M. hyo bacterin, or an immunogenic composition comprising M. hyo bacterin, and at least one immunogenic active component of another disease-causing organism in swine, preferably PCV2 wherein the preferred PCV2 antigen for such a multivalent vaccine is PCV2 ORF 2 protein.
Abstract translation: 提供了多价组合疫苗，其包括有效减少猪尾杆菌感染的发生率或降低其重要性的免疫学试剂，优选猪尾杆菌属细菌，或包含猪肺炎支原体菌的免疫原性组合物，和至少一种免疫原性活性成分 猪中另一种致病生物，优选PCV2，其中用于这种多价疫苗的优选PCV2抗原是PCV2 ORF 2蛋白。
-
公开(公告)号：US07622124B2
公开(公告)日：2009-11-24
申请号：US11652306
申请日：2007-01-11
Applicant: Hsien-Jue Chu , Wumin Li , Zhichang Xu
Inventor： Hsien-Jue Chu , Wumin Li , Zhichang Xu
IPC: A61K39/295
CPC classification number: A61K9/0024 , A61K39/0241 , A61K39/12 , A61K39/145 , A61K39/39 , A61K47/06 , A61K47/10 , A61K47/32 , A61K2039/521 , A61K2039/525 , A61K2039/552 , A61K2039/55555 , A61K2039/55566 , A61K2039/70 , C12N7/00 , C12N2760/16134 , Y02A50/48
Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosol and/or EDTA. In another embodiment, the invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration, and comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant or adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity, in combination with other vaccine components.
Abstract translation: 本发明提供了一种改良的猪肺炎支原体疫苗组合物，其在单次给药后有利地提供免疫感染。 组合物包含灭活的猪肺炎支原体疫苗和佐剂混合物，其组合在单次施用后提供对猪肺炎支原体感染的免疫，并引起对猪肺炎支原体菌苗特异性的免疫应答，并且包括细胞介导的免疫和局部（分泌型IgA ）免疫力。 在优选的实施方案中，佐剂混合物包含丙烯酸聚合物，最优选的是CARBOPOL，以及可代谢的油如一种或多种不饱和萜烯烃（优选角鲨烯或角鲨烷）和聚氧乙烯 - 聚丙烯嵌段共聚物 作为PLURONIC（R）。 疫苗组合物可以任选地包括防腐剂，优选硫柳汞和/或EDTA。 在另一个实施方案中，本发明提供了改进的猪肺炎支原体疫苗组合物，其有利地在单次施用后提供免疫感染，并且包含灭活的猪肺炎支原体菌苗和佐剂或佐剂混合物，其组合提供猪肺炎支原体 单次给药后感染，并引起特异于猪肺炎支原体菌的免疫应答，并与其他疫苗组分结合使用，包括细胞介导的免疫和局部（分泌型IgA）免疫。
-
公开(公告)号：US20090220550A1
公开(公告)日：2009-09-03
申请号：US11982079
申请日：2007-10-31
Applicant: Joan D. Leonard , Robert W. Tully
Inventor： Joan D. Leonard , Robert W. Tully
CPC classification number: A61K39/0241 , A61K2039/521 , A61K2039/522 , A61K2039/552 , A61K2039/555 , A61K2039/55505 , A61K2039/55566
Abstract: The invention of novel, effective vaccines against Mycoplasma bovis for use in cattle is described. These vaccines demonstrate no undesirable side effects and protect against M. bovis related disease, such as contagious mastitis, respiratory pneumonia, joint infections, keratoconjunctivitis and middle ear infections. The novel vaccines also lessen the effect of M. bovis infections on milk production, weight gain and animal health. Methods of diagnosing, characterizing and treating M. bovis infections as specific biotypes are also disclosed. Vaccine compositions made in accordance with the invention may be either of the attenuated or inactivated variety. Vaccines may also include antigens from other pathogens so as to provide a protective immunogenic response to diseases other than those caused by M. bovis.
Abstract translation: 描述了用于牛用于牛支原体的新型有效疫苗的发明。 这些疫苗不表现出不希望的副作用，并且防止牛分枝杆菌相关疾病，如传染性乳腺炎，呼吸性肺炎，关节感染，角膜结膜炎和中耳感染。 新型疫苗也可以减轻牛分枝杆菌感染对牛奶生产，体重增加和动物健康的影响。 还公开了将牛分枝杆菌感染诊断，表征和治疗作为特定生物型的方法。 根据本发明制备的疫苗组合物可以是减毒或灭活的品种。 疫苗还可以包括来自其他病原体的抗原，以便对除牛分枝杆菌引起的疾病以外的疾病提供保护性的免疫原性应答。
-
37.发明授权Preparation of vaccine master cell lines using recombinant plant suspension cultures 失效使用重组植物悬浮培养物制备疫苗主细胞系
公开(公告)号：US07553666B2
公开(公告)日：2009-06-30
申请号：US11585040
申请日：2006-10-23
Applicant: Charles A. Mihaliak , Matthew J. Fanton , Janis K. McMillen
Inventor： Charles A. Mihaliak , Matthew J. Fanton , Janis K. McMillen
CPC classification number: A01H4/001 , A01H4/005 , A61K39/0241 , A61K39/12 , A61K39/145 , A61K39/17 , A61K2039/517 , C07K14/005 , C12N5/0025 , C12N15/8257 , C12N15/8258 , C12N2720/10022 , C12N2720/10034 , C12N2760/16122 , C12N2760/16134 , C12N2760/18122 , C12N2760/18134
Abstract: The subject invention provides a plant cell culture for producing proteinaceous agents comprising a plant cell line stably transformed to express a transgene encoding a proteinaceous agent and a growth medium which supports the growth of said plant cell culture but which does not support the growth of Mycoplasmataceae and contains no materials of animal origin. The plant cell line is capable of being continuously passaged such that consistent transgene expression is maintained during passaging. The plant cell line is also capable of being cryopreserved such that consistent transgene expression is recovered upon recovery from cryopreservation.
Abstract translation: 本发明提供了用于生产蛋白质物质的植物细胞培养物，其包含稳定转化以表达编码蛋白质试剂的转基因的植物细胞系和支持所述植物细胞培养物生长但不支持支原体生长的生长培养基， 不含动物来源的材料。 植物细胞系能够连续传代，使得在传代期间保持一致的转基因表达。 植物细胞系也能够被冷冻保存，使得从冷藏保存回收后可以恢复一致的转基因表达。
-
公开(公告)号：US20090068232A1
公开(公告)日：2009-03-12
申请号：US12207750
申请日：2008-09-10
Applicant: Mahesh Kumar , Muhammad Ayub Khan
Inventor： Mahesh Kumar , Muhammad Ayub Khan
CPC classification number: C12N1/36 , A61K39/0241 , A61K2039/522 , A61K2039/552 , C12N1/20 , C12R1/35
Abstract: The present invention provides live, attenuated Mycoplasma gallisepticum bacteria that exhibit reduced expression of a protein identified as MGA_0621. In certain embodiments, the attenuated bacteria may additionally exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type M. gallisepticum bacterium. Also provided are vaccines and vaccination methods involving the use of the live, attenuated M. gallisepticum bacteria, and methods for making live attenuated M. gallisepticum bacteria. An exemplary live, attenuated strain of M. gallisepticum is provided, designated MGx+47, which was shown by proteomics analysis to exhibit significantly reduced expression of MGA_0621, and was shown to be safe and effective when administered as a vaccine against M. gallisepticum infection in chickens.
Abstract translation: 本发明提供活的，减毒的鸡毒支原体细菌，其表现出被鉴定为MGA_0621的蛋白质的表达降低。 在某些实施方案中，相对于野生型M，减毒细菌可另外表现出一种或多种选自丙酮酸脱氢酶，磷酸丙酮酸水合酶，2-脱氧核糖-5-磷酸醛缩酶和核糖体蛋白L35的蛋白质的表达降低 胆汁败霉菌 还提供了涉及使用活的，减毒的金黄色葡萄球菌细菌的疫苗和疫苗接种方法，以及用于制造活的减毒的金黄色葡萄球菌细菌的方法。 提供了一种示例性的活的减毒毒株的菌株，命名为MGx + 47，通过蛋白质组学分析显示出显着降低的MGA_0621的表达，并且当作为针对鸡链球菌毒素感染的疫苗施用时被证明是安全和有效的 在鸡中
-
公开(公告)号：US20080014221A1
公开(公告)日：2008-01-17
申请号：US11711358
申请日：2007-02-27
Applicant: Gregory Royer , Russell Howser , Catherine Charreyre , Francis Milward
Inventor： Gregory Royer , Russell Howser , Catherine Charreyre , Francis Milward
IPC: A61K39/04
CPC classification number: A61K39/0241 , A61K2039/54 , A61K2039/55566
Abstract: The invention provides a novel method of vaccination of a pig against Mycoplasma hyopneumoniae by administering to a weaned piglet or a sow, a single dose of an effective amount of a Mycoplasma hyopneumoniae vaccine. The Mycoplasma hyopneumoniae vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine.
Abstract translation: 本发明提供了一种通过对断奶仔猪或母猪施用单剂量的有效量的猪肺炎支原体疫苗来接种针对猪肺炎支原体的猪的新方法。 肺炎支原体疫苗可以是全部或部分细胞灭活或修饰的活体制剂，亚单位疫苗或核酸或DNA疫苗。
-
40.发明申请Vaccine compositions for vaccinating dogs against canine infectious respiratory disease 有权疫苗组合物用于疫苗接种犬用于犬传染性呼吸道疾病
公开(公告)号：US20070098739A1
公开(公告)日：2007-05-03
申请号：US10563199
申请日：2004-07-01
Applicant: John Brownlie , Victoria Chalker , Kerstin Erles
Inventor： John Brownlie , Victoria Chalker , Kerstin Erles
IPC: A61K39/116
CPC classification number: G01N33/6854 , A61K39/0241 , A61K39/092 , A61K39/118 , A61K2039/505 , A61K2039/552 , G01N2333/295 , G01N2333/30 , G01N2333/315 , G01N2800/12
Abstract: A vaccine composition for vaccinating dogs comprising any one or more of (a) an agent capable of raising an immune response against Streptococcus equi sub species zooepidemicus in a dog, (b) an agent capable of raising an immune response against Mycoplasma cynos in a dog, and (c) an agent capable of raising an immune response against a Chlamydophila in a dog.
Abstract translation: 一种用于疫苗接种疫苗的疫苗组合物，其包含以下一种或多种：（a）能够对狗中的链球菌属动物疫苗提供免疫应答的试剂，（b）能够增加狗中支原体的免疫应答的试剂 ，和（c）能够在狗中提高针对衣原体的免疫应答的药剂。
